...
首页> 外文期刊>Chinese Journal of Clinical Oncology >Preoperative Chemoradiotherapy for Inflammatory Breast Cancer
【24h】

Preoperative Chemoradiotherapy for Inflammatory Breast Cancer

机译:炎性乳腺癌的术前放化疗

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE To observe the effect of preoperative chemoradiotherapy for inflammatory breast cancer. METHODS From December 1996 to December 2000, we received and treated 21 patients with inflammatory breast carcinoma with a combined-modality treatment. The chemotherapy protocol consisted of cyclophos-phamide (CTX), pirarubicin (THP-ADM) and 5-fluorouracil (5-FU) or CTX, 5-Fu and methotrexate (MTX). The same infusion scheme was repeated on day 21. After 3-4 cycles the patients were treated with radiotherapy. When the radiation dose reached 40 Gy, the patients who were unable or unwilling to under go an operation received continued radiotherapy. When the radiation dose to the supra clavicular fossa and internal mammary lymph nodes reached 60 Gy and 50 Gy respectively, the radiotherapy was stopped. Chemotherapy was then continued with the original scheme. Patients who had indications for surgery and were willing to under go an operation received no treatment for 2 weeks, after which a total mastectomy was performed. Chemotherapy and radiotherapy was resumed with the original scheme after the operations. When the radiation dose reached 50 Gy, radiotherapy was stopped. RESULTS All patients were followed-up for more than 5 years with a follow-up rate of 100%. The overall 3 and 5-year survival rates of these patients were 42.9%, and 23.8% respectively. For patients in Stage Ⅲ_B the 3 and 5-year survival rates were 50.0% and 27.8% respectively, and for patients in Stage Ⅳ, the 3 and 5-year survival rates were both 0.0%. There was a significant difference between the 2 stage groups (P < 0.05, χ~2 = 11.60). For patients who received an operation, the 3 and 5-year survival rates were 80.0% and 33.3% respectively, For patients who were not treated with an operation, the 3 and 5 -year survival rates were both 0.0%, There was a significant difference between the operated and non-operated groups (P < 0.05, χ~2 = 11.64). CONCLUSION The prognosis of inflammatory breast carcinoma is poor. Before operation, a combined -modality treatment (first chemotherapy, then local therapy, finally chemotherapy and radiotherapy) is the best treatment method.
机译:目的观察炎性乳腺癌术前放化疗的疗效。方法从1996年12月至2000年12月,我们接受了联合方式治疗21例炎症性乳腺癌患者。化疗方案包括环磷酰胺(CTX),吡柔比星(THP-ADM)和5-氟尿嘧啶(5-FU)或CTX,5-Fu和甲氨蝶呤(MTX)。在第21天重复相同的输注方案。3-4个周期后,对患者进行放射治疗。当放射剂量达到40 Gy时,无法或不愿进行手术的患者将继续接受放射治疗。当锁骨上窝和乳腺内部淋巴结的放射剂量分别达到60 Gy和50 Gy时,停止放疗。然后继续使用原始方案进行化学疗法。有手术指征并愿意进行手术的患者在2周内未接受任何治疗,之后进行了全乳房切除术。手术后按原计划恢复化疗和放疗。当放射剂量达到50 Gy时,停止放疗。结果所有患者均获随访5年以上,随访率100%。这些患者的总体3年和5年生存率分别为42.9%和23.8%。 Ⅲ_B期患者的3年和5年生存率分别为50.0%和27.8%,而Ⅳ期患者的3年和5年生存率均为0.0%。 2个阶段组之间存在显着差异(P <0.05,χ〜2 = 11.60)。对于接受手术的患者,其3年和5年生存率分别为80.0%和33.3%,对于未经手术治疗的患者,其3年和5年生存率均为0.0%,手术组和非手术组之间的差异(P <0.05,χ〜2 = 11.64)。结论炎性乳腺癌的预后较差。术前综合治疗(先化疗,然后局部治疗,最后是化疗和放疗)是最好的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号